Growth Hormone Secretagogues

CJC-1295 with DAC

Also known as CJC-1295 DAC · Drug Affinity Complex CJC-1295 · DAC:GRF

PreliminarySubcutaneous injectionNot FDA-approved for any indication. The CJC-1295 substance was removed from FDA's interim Category 2 bulk-substances list in September 2024, and subsequent Pharmacy Compounding Advisory Committee review did not establish a 503A compounding pathway, leaving its compounding status unresolved. Prohibited in sport (WADA, S2). Research/compounded use only.

CJC-1295 with DAC is a GHRH analog bonded to a Drug Affinity Complex that allows it to bind circulating albumin, substantially extending its duration of action in animal studies. Rather than producing a single sharp pulse, it has been described as raising baseline growth-hormone and IGF-1 levels over a sustained period. This prolonged, less physiologic growth-hormone elevation is the feature most often cited to distinguish it from the short-acting DAC-free version. It is an unapproved compound studied only in research and compounded contexts.

Studied / used for

Studied for sustained elevation of growth hormone and IGF-1
Explored for effects on body composition
Investigated as a longer-acting alternative to short-acting GHRH analogs

Commonly reported side effects

Injection-site reactions
Flushing
Headache
Fluid retention and peripheral edema
Joint aches or numbness/tingling reported in the context of IGF-1 elevation

Preliminary. Mostly early or animal studies. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds